Trials / Completed
CompletedNCT00950417
Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
Phase I Study of Nimotuzumab in Combination With Simultaneous Chemotherapy and Radiation for Patients With Locally Advanced Esophageal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Biotech Pharmaceutical Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The phase I study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemo-radiotherapy in patients with locally advanced esophageal cancer tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-07-01
- Completion
- 2012-11-01
- First posted
- 2009-07-31
- Last updated
- 2015-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00950417. Inclusion in this directory is not an endorsement.